Publications

Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance

Published in Cancer Cell, 2023

Using clinical data on human melanoma and urothelial carcinoma and murine models, we show that MTAP deletion and accumulation of MTA lead to an immune cold microenvironment through effects on both PRMT5 and adenosine receptors.

Recommended citation: Gjuka, D., Adib, E., Garrison, K., Chen J., Zhang Y., Li W., Boutz D., Lamb C., Tanno Y., Nassar A., Zarif T., Kale N., Rakaee M., Mouhieddine T., Alaiwi A., Gusev A., Rogers T., Gao J., Georgiou G., Kwiatkowski D., Stone E. (2023). "Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance." Cancer Cell, 41. 1-14. https://doi.org/10.1016/j.ccell.2023.09.005

Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune checkpoint inhibitors (ICI) in advanced solid tumors

Published in Journal of Clinical Oncology, 2022

This paper investigates the impact of CDKN2A and MTAP genomic alterations on the response to immune checkpoint inhibitors in cancer patients and finds that the co-occurrence of MTAP/CDKN2A alterations is associated with poorer outcomes, particularly in urothelial carcinoma and melanoma, accompanied by lower tumor-infiltrating lymphocyte density in melanoma samples with both alterations.

Recommended citation: Adib, E., Nassar, A., El Zarif, T., Kale, N., Rakaee, M., Mouhieddine, T. H., Abou Alaiwi, S., Freeman, D., Labban, M., Akl, E., Haddad, R. I., Hodi, F. S., Sonpavde, G. P., Giannakis, M., Braun, D. A., Gusev, A., Choueiri, T. K., Overstreet, E., Stone, E., & Kwiatkowski, D. J. (2022). "Dual CDKN2A/MTAP loss compared to CDKN2A loss alone and response to immune-checkpoint inhibitors (ICI) in advanced solid tumors." Journal of Clinical Oncology, 40(16_suppl), 2622–2622. https://doi.org/10.1200/jco.2022.40.16_suppl.2622